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technical analysis
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Abstract
Platelet-rich plasma (PRP) is blood plasma with a high concentration of autologous platelets
which constitute an immense reservoir of growth factors. The clinical use of PRP is widespread
in various medical applications.
Although highly popular with athletes, the use of PRP for the treatment of tendinopathies
remains scientifically controversial, particularly due to the diversity of products that go by the
name of “PRP.” To optimize its use, it is important to look at the various stages of obtaining
PRP.
In this literature review, we take a closer look at eight parameters which may influence the
quality of PRP: 1) anticoagulants used to preserve the best platelet function, 2) the speed of
centrifugation used to extract the platelets, 3) the platelet concentrations obtained, 4) the
impact of the concentration of red and while blood cells on PRP actions, 5) platelet activators
encouraging platelet degranulation and, hence, the release of growth factors, and 6) the use or
nonuse of local anesthetics when carrying out infiltration. In addition to these parameters, it
may be interesting to analyze other variables such as 7) the use of ultrasound guidance during
the injection with a view to determining the influence they have on potential recovery.
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Introduction
Platelet-rich plasma (PRP) consists of blood plasma with a high
concentration of autologous platelets which constitute an
immense reservoir for growth factors [1,2], as PDGF (Platelet-
Derived Growth Factor), IGF-1 (Insuline-Like Growth Factor),
TGF-β (Transforming Growth Factor), EGF (Epidermal Growth
Factor), VEGF (Vascular Endothelial Growth Factor), etc. These
are essential for the initiation and stimulation of the healing
mechanism and the synthesis of collagen among other actions
[3,4]. The clinical use of PRP is widespread in various areas such
as maxillo-facial surgery, sports traumatology, orthopedic sur-
gery, and dermatology [5–7].
The conservative treatment of tendinopathies is difficult, and
pain remains often rebel to classic treatments [8,9]. This is why
new treatments, including PRP, are currently being assessed.
Although highly popular with athletes, however, its use remains
scientifically controversial [10–12], particularly of products and
kits available in the market as PRP and also due to different
methodologies and lack of standardization to obtain PRP [13–
15]. To optimize its use, it is important to take a look at the
various stages of obtaining PRP [16].
We decided to carry out a literature review and, more specifi-
cally, to analyze eight parameters which can influence the quality
of PRP: 1) anticoagulants used to preserve the best platelet
function, 2) the speed of centrifugation used to extract the plate-
lets, 3) the platelet concentrations obtained, 4) the presence of
leukocytes and erythrocytes in the PRP, 5) platelet activators
encouraging platelet degranulation and, hence, the release of
growth factors, and 6) the use or nonuse of local anesthetics
when carrying out infiltration. In addition to these parameters, it
may be interesting to analyze other variables such as 7) the use of
ultrasound guidance during the injection with a view to determin-
ing the influence they have on potential recovery.
Material and methods
A search for articles was conducted in the Pubmed and Pedro
databases. The results were obtained by using the following key
words and combinations of these key words: PRP, platelet-rich
plasma, injection, treatment, tennis elbow, greater trochanteric
pain syndrome, jumper’s knee, Achilles tendinopathy, plantar
fasciitis, anticoagulant, sodium chloride, local anesthetic, and
centrifugation speed.
Results
The studies are given in chronological order in the form of
summary tables according to the type of tendinopathy treated
(Tables I–IV) [17–69].
Anticoagulant
The choice of anticoagulant capable of preserving the greatest
platelet integrity and functionality is an important factor. In
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terms of the type of anticoagulant, most authors agree on the
nonuse of EDTA (ethylene diamine tetra-acetic acid) which
may damage the platelet membrane. Hence, we will focus on
the use of anticoagulants containing citrate-dextrose or
sodium citrate [70].
Acid-citrate-dextrose (ACD) is an anticoagulant used by blood
banks to store viable platelets for transfusion. ACD can maintain
platelet viability for six hours [71]. In a study analyzing the
effects of anticoagulants on PRP quality, Lei et al. [72] high-
lighted that ACD maintains the integrity of the structure of
platelets in the PRP for up to 12 hours. However, when heparin
sodium and sodium citrate are used, half of the platelets begin to
rupture in the first hours. The positive effect of ACD on main-
taining platelet viability may be due to glucose and the low citrate
concentration [73]. One alternative to ACD-A is citrate phosphate
dextrose-adenine (CPDA). This anticoagulant is similar, but is
10% less effective in terms of maintaining platelet viability [74].
Centrifugation speed
Several factors may influence the integrity of platelets as well as
the composition and effectiveness of PRP. These include the
number of revolutions per minute (RPM), centrifugal acceleration
and duration of centrifugation, and angular speed and distance
separating the platelets from the rotor axis.
Perez et al. [75] attempted to highlight elements of the cen-
trifugation stage required to obtain reproducible and high-quality
results. Blood samples were taken from 20 healthy donors. Two
stages of centrifugation were analyzed to identify the influence of
centrifugal acceleration, duration, the volume treated, and the
platelet gradient. They concluded that low centrifugal promoted
the separation of PRP. Treating 3.5 ml of blood at 100g for
10 minutes (first centrifugation) followed by a second centrifuga-
tion at 400g for 10 minutes, which had previously removed 2/3 of
the remaining plasma, enabled a higher rate (70–80%) and higher
concentration (5x) of platelets to be recovered while maintaining
platelet integrity and viability. When using a larger volume
(8.5 ml), platelet recovery was lower. The authors therefore con-
cluded that centrifugal acceleration, the duration of centrifuga-
tion, the platelet gradient prior to sampling, and the volume
treated were the main elements to be retained in order to ensure
a reproducible composition of PRP.
In contrast to the study by Perez et al. [75], a recent study by
Arora et al. [76] showed better results with centrifugal accelera-
tion of 440g for 10 minutes. This difference may be due to the
difference in the initial volume used for the preparation of PRP.
There are numerous protocols in the current literature which
describe the optimal conditions for centrifugation.
Platelet concentration
To date, very few studies have been carried out on the optimal
dosage of platelets in PRP. Numerous researchers have, however,
suggested that platelet concentration must be three to seven times
higher than that found in peripheral blood (between 150,000 and
350,000 platelets/μL) [77,78]. Weibrich et al. [79] assessed, in
vivo, the effects of different platelet concentrations on bone
regeneration. He found that the use of platelet concentrate had
positive effects, on the condition that the platelet concentration
was approximately between 503,000 and 1,729,000 platelets/μL
(1.5 to 4.5 times the concentration of platelets in peripheral
blood). Indeed, the use of an excessively high platelet rate (6 to
12 times the concentration of platelets in peripheral blood)
appeared to have an inhibitory effect on healing. Graziani et al.
[78] assessed the effect of different concentrations of PRP on
osteoblast and fibroblast function in vitro. The results of this
study showed that PRP has a maximum effect when obtained
with a platelet concentration which is 2.5 times higher than the
concentration in peripheral blood. Increased concentrations lead
to a reduction in the proliferation of osteoblasts and fibroblasts,
suggesting a paradoxical inhibitory effect on tissue regeneration.
The large variety of platelet concentrations encountered in
many studies is explained by the use of commercial kits to
prepare PRP. The results of these kits vary significantly from
one patient to another but also from one sample to another for
the same patient [13,14]. Only use of an apheresis machine can
obtain a constant concentration and reproducibility for each
patient [80]. The donation of blood components through apheresis
has become commonplace in modern blood transfusion practices.
Technological progress in automated cell separators has improved
the productivity and quality of platelet collection through apher-
esis [81]. There are a wide variety of instruments to extract
platelets through apheresis, and many studies have compared
different cell separators. Of those, Keklik et al. [82] compared
three apheresis systems (Fenwal Amicus, Fresenius COM.TEC
and Trima Accel) in terms of processing time, platelet output,
efficiency, and speed of collection. The results showed that the
volume of blood treated, the volume of ACD-A, and the average
separation time were significantly higher with the COM.TEC
system.
Altuntas et al. [83] compared two apheresis systems (Fenwal
Amicus and Fresenius COM.TEC), comparing processing time,
platelet output, efficiency of collection, and white cell content.
The results obtained showed that both instruments collected pla-
telets efficiently with an equal leukocyte content; however,
Amicus achieved the desired platelet rate more quickly.
Moog et al. [80] demonstrated that the COM.TEC machine
enabled platelet concentrates to be acquired with a lower rate of
leukocytes meeting the standards in place. To do so, five centers
collected 554 samples using the COM.TEC cell separator. Two
cell counting studies were carried out at the start and at the end of
the study to confirm a uniform count between the participating
centers.
The impact of the concentration of red and while blood cells
on PRP actions
The presence of red and white blood cells in the PRP may also
impact upon the effectiveness of the treatment.
Indeed, the lysis of erythrocytes can cause the generation of
highly reactive oxygen metabolites (also called oxygen-deviated
free radicals) which can cause tissue damages and may hinder the
healing process [84].
Moreover, the release of pro-inflammatory factors (cytokine
and metalloproteinase) by the leukocytes may lead to deteriora-
tion of the extracellular matrix. Zhang et al. [85] published the
hypothesis that PRP containing high levels of leukocytes (L-PRP)
increases the concentration of catabolic cytokine and induces
inflammation and apoptosis of tendon cells. This study compared
the effects of L-PRP and PRP on the morphology, proliferation,
and differentiation of tendon cells. The results of this study
showed that L-PRP has negative effects on tendon stem cells by
inhibiting their proliferation, accelerating their differentiation and
inducing their apoptosis. McCarrel et al. [86] also came to the
conclusion that a low concentration of leukocytes leads to a
reduction in the inflammatory expression of cytokines. Another
study carried out on patellar tendons in white mice by Dragoo et
al. [87] compared the inflammatory effects of an injection of PRP
containing high levels of leukocytes (L-PRP) to those of an
injection of PRP with few leukocytes. The results showed that
the L-PRP provoked a significant inflammatory response for five
days after the injection. The authors observed an increased rate of
DOI: https://doi.org/10.1080/09537104.2017.1336211 The use of platelet-rich plasma to treat chronic tendinopathies 223
leukocytes and mononuclear cells (macrophages and lympho-
cytes) in the tendons treated with L-PRP in comparison to those
treated with PRP. They also noted an increase in vascularization
and fibrosis of these tissues.
Pizza et al. [88] studied the effects of neutrophiles (pro-inflam-
matory factors) on the extracellular muscle matrix. It appeared that
the neutrophiles could damage the skeletal myotubes in vitro and
aggravate injuries or delay tissue regeneration in vivo.
With these observations, we recommend the use of leukocyte
poor PRP (and without any erythrocytes) to avoid any local
inflammatory reaction which can be painful for the patient and
reduce the proliferative phase of the healing process. However, in
the clinical literature in human, the results can also be good with
the use of L-PRP; the disparity of the PRP used would be
responsible for the variability of the results obtained. Thus, a
general agreement on the preparation and the type of the PRP to
use in orthopedics is still need.
Platelet activator
Activation of PRP prior to the injection is another parameter
which requires in-depth examination. Platelet activation leads to
the degranulation of alpha granules. The release of numerous
proteins and growth factors (including PDGF, TGF-β, VEGF,
and IGF) stimulates the healing process [10,89]. Platelets may
be activated exogenously by thrombin, calcium chloride, or as the
result of mechanical trauma. Denatured collagen is a natural PRP
activator, and when used within soft tissue, exogenous activation
is not always necessary [90,91].
Once the PRP is activated, a fibrin network starts to form,
solidifying plasma and creating a fibrin clot or membrane which
contributes toward tissue healing. According to Weibrich et al.
[92], no significant changes in platelet or growth factor concen-
tration are observed according on the patient’s age or sex. Several
studies, however, report that the hematocrit and total platelet level
influence the platelet concentration of PRP [92,93]. Indeed, the
higher the hematocrit and platelet levels are, the greater the
platelet concentration will be.
A study by Martineau et al. [94] showed that PRP activation
with a high concentration of calcium and thrombin leads to an
immediate and significant increase in the release of growth factors.
Local anesthetic
Although intratendon injections are painful, the use of a local
anesthetic is not recommended as it may compromise the thera-
peutic potential of PRP: The anesthetic may reduce local pH,
leading to an inhibition, reduction, or absence of platelet degra-
nulation [16]. This hypothesis has been confirmed by Bausset et
al. [95] who showed that the association formed by a local
anesthetic (lidocaine, ropivacaine) and PRP injections in vitro
leads to a significant reduction in platelet functionality, in parti-
cular platelet aggregation. He therefore recommends using smal-
ler needles. Carofino et al. [96] tried to identify the effects of the
association formed by an anesthetic (lidocaine, bupivacaine) or a
corticosteroid (methylprednisolone) and PRP on human tenocytes
in vitro. He came to the conclusion that adding one or the other to
the PRP resulted in a significant reduction in tenocyte prolifera-
tion and cell viability.
Ultrasound guidance
Many studies do not use ultrasound guidance. In such cases, the
area to be treated is identified by palpation, followed by a series
of injections in order to obtain complete coverage of the site [97].
The growing use of ultrasound to guide injections enables the
PRP injection into the pathological tendon to be visualized. The
basic principle of PRP is to inject a high concentration of active
proteins and growth factors to the injury site. It would, therefore,
appear relevant to identify the extent to which the product effec-
tively remains at the injection site and what quantity is dispersed
into the surrounding tissue. It has, nonetheless, been demon-
strated that PRP diffused several centimeters from the injection
site in the minutes following infiltration [97].
Discussion
Although there is an increasing amount of scientific proof about the
benefits of PRP infiltration in the treatment of tendinopathies, there
is currently no consensus as to how to obtain or use it. This may
partly explain the disparity of results obtained in the literature.
Similarly, the biological parameters and risk factors for tendinopa-
thies of patients themselves may possibly influence the results of this
treatment even if, to date, this has not yet been demonstrated [98].
Analysis of these studies (Tables I–IV) shows that a majority
use ACD-A as an anticoagulant during sampling. By comparing
the results of studies using ACD-A and sodium citrate (seven
studies), we were able to highlight the greater effectiveness of
ACD-A. However, the small number of studies using sodium
citrate does not allow us to confirm this hypothesis.
A platelet activator is only used in a few studies (eight studies).
Of those, calcium chloride is the main product used. Each study
using this platelet activator presents positive results. However, the
best results have been obtained in studies which use no platelet
activator.
It is, however, important to note that the results are obtained
by adding a range of variables which are not reproducible from
one study to the next (anticoagulant, platelet activator, local
anesthetic, speed of centrifugation, pH buffer, ultrasound gui-
dance, volume of PRP injected). As such, it is impossible to
draw conclusions about the greater effectiveness of ACD-A and
the real value of using a platelet activator.
In terms of the speed of centrifugation, analysis of all these
studies appears to confirm the existence of a great number of
protocols in the literature. It is difficult to draw any conclusions
when these different variables are unknown (volume of initial
sample, equipment used to obtain the PRP).
Currently, no studies have been carried out neither on the use
of a “buffer” product to neutralize the acidity caused by the
anticoagulant nor on the optimal volume of PRP to be injected.
Although it would appear inadvisable to administer a local
anesthetic because the anesthetic may reduce the local pH and
lead to the inhibition, reduction, or absence of platelet degranula-
tion, the literature shows that the majority use a local anesthetic
(32 studies out of 57). They do not, however, obtain better results
than those not using a local anesthetic.
Finally, it appears to be advisable to carry out infiltration
under ultrasound guidance, even if PRP diffusion is observed
after injection.
This all aims to show that there is still a need for high quality
studies, with standardized collection protocols and the use of PRP
in the context of tendinopathies, in order to better scientifically
understand the real effectiveness.
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